DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Regulation and Action of SKP2 in Cell and Tumor Models: Mechanisms Underlying Aggressive Growth in Basel-Like Breast Cancer
Annual summary rept. 15 May 2008-14 May 2009
MASSACHUSETTS UNIV AMHERST
Pagination or Media Count:
The objective of this research is to further our understanding of the molecular mechanisms underlying the aggressive growth of estrogen receptor ER-negative, basal-like breast tumors. My goal is to determine if SKP2 is a viable new therapeutic target to specifically treat patients who have tumors that are independent of ER signaling. The most significant finding during this research period is that SKP2 protein was expressed in 60 21 of 35 of ER-negative tumors, 25 26 of 104 of ER-positive tumors, and 10 5 of 50 reductive mammoplasty tissues. These data suggest that SKP2 overexpression is a phenomenon associated with ER-negative tumors. With an additional 150-300 ER-negative tumor cases this relationship will be better elucidated.
APPROVED FOR PUBLIC RELEASE